An interventional study of Test condom A (NRL condom with 5% benzocaine paste) and Test condom B (NRL condom with 3% benzocaine paste) in Ejaculation Delayed, sponsored by Reckitt Benckiser Healthcare (UK) Limited. Completed at 1 site in Germany. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-07.
Sponsored by Reckitt Benckiser Healthcare (UK) Limited (part of Reckitt) · Not applicable, Interventional, and Other
The investigation is to evaluate the effectiveness of benzocaine in two NRL condoms compared with a standard NRL control without benzocaine in prolonging time to ejaculation in healthy adult men who feel they ejaculate too quickly during vaginal sex.
In this investigation, two NRL condoms with benzocaine paste (Test condom A and Test condom B) will be evaluated against a standard NRL male condom (Control condom) in prolonging time to ejaculation in healthy adult men who feel they ejaculate too quickly during vaginal sex.
Reckitt Benckiser Healthcare (UK) Limited is the lead sponsor of 35 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Main Exclusion Criteria:
Subject and/or his female partner have a physical or psychological condition that would prevent them from following investigation procedures - including but not limited to the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
Device: Test condom A (NRL condom with 5% benzocaine paste)
Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
Device: Test condom B (NRL condom with 3% benzocaine paste)
Following randomization, each subject will be given one set of 8 condoms as per randomisation schedule. After reporting at least 4 duration records (from vaginal entry to ejaculation), subjects will return to the clinical site for collection of their next set of condoms.
Device: Control NRL condom
In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
In each assessment period, subjects will be provided with a condom type to use during vaginal intercourse and will report at least 4 duration records (from vaginal entry to ejaculation) over a 4-week period. Subjects will repeat the assessment period each to test all 3 condom types.
To Determine the Effectiveness of Benzocaine of the Test Condom A Compared With the Control NRL Condom at Prolonging Time to Ejaculation
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom A compared to the Control NRL Condom, over a 4-week assessment period. This outcome was to measure the per participant's average IELT time per condom type. The Intravaginal Ejaculation Latency Time (IELT) is the duration from the start of vaginal entry (vaginal penetration into the female partner) until the start of intravaginal ejaculation (release of semen). It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model. This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
To Determine the Effectiveness of Benzocaine of the Test Condom B Compared With the Control NRL Condom at Prolonging Time to Ejaculation
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom B compared to the Control NRL Condom, over a 4-week assessment period. This outcome was to measure the per participant's average IELT time per condom type. It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model. This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
To Determine the Effectiveness of Benzocaine of the Test Condom A and Test Condom B Compared With the Control NRL Condom at Prolonging Time to Ejaculation for an Increase of 2, 3 and 4 Minutes
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the proportion of participants who achieved an increase of 2, 3 and 4 minutes from baseline in each of the Test Condom A and Test Condom B compared to the Control NRL Condom. The odds ratio compares the odds of achieving a given duration increase (e.g., ≥2 minutes) with Test Condom A or B to the odds of achieving the same increase with the Control Condom. An odds ratio greater than 1 suggests the test condom is more effective than the control in helping participants reach that milestone. This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
To Evaluate the Sexual Pleasure When Using the Test Condom A or Test Condom B Compared With the Control NRL Condom
The outcome was assessed by the measure of EMSEX (Event-level Male Sexual) pleasure scale questionnaire, a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. EMSEX pleasure scale is a 11-item scale which assesses sexual pleasure at the event level. For each item, the range spans the entirety of the potential range from 0 (zero) to 100 (one hundred). This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
To Evaluate the Subject's Improvement at "Lasting Longer" for Both the Test Condom A and Test Condom B Compared With the Control NRL Condom
The outcome was assessed by the measure of Patient Global Impression of Change (PGIC), a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. The PGIC is a 7-point response scale (Very much better, Better, Little better, No change, Little worse, Worse, Very much worse). This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Participant - Subject Perceived Questionnaire (SPQ)
Upon completion of each condom assessment period, each participant was required to complete a SPQ. The questionnaire collected the following information (including but not limited to): experience with condom use, acceptability, preference and tolerability. This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Total Clinical Failure Rate of Each Type of Condoms
Number of clinical failure events per usages (clinical slippage or clinical breakage) reported by participants. The number of outcomes are based on the number of sexual encounters while wearing one of the three condoms being tested. This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 4 weeks for each assessment period (intervention duration)
Overall Proportion of Participants With Adverse Events/Adverse Device Effects (AE/ADEs) - Male Participants
Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant. The result is presented by the counts of all AEs sorted by SOC and PT for male participants. This outcome measure data was collected and analyzed for 150 male participants.
Time frame: 19 weeks
Overall Proportion of Participants With Adverse Events/Adverse Device Effects (AE/ADEs) - Female Participants
Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant. The result is presented by the counts of all AEs sorted by SOC and PT for male participants. This outcome measure data was collected and analyzed for 150 female participants.
Time frame: 19 weeks
218 couples were screened for eligibility at a clinical site in Germany. 150 of 218 couples (300 participants) were randomized. Of those not randomized, 68 couples were screen failures. Each couple was randomized to use condoms by sequence. The randomized sequences were A/B/Control, A/Control/B, B/A/Control, B/Control/A, Control/A/B, Control/B/A.
| Milestone | A/B/Control | A/Control/B | B/A/Control | B/Control/A | Control/A/B | Control/B/A |
|---|---|---|---|---|---|---|
| Started | 25 | 25 | 25 | 25 | 25 | 25 |
| Male participants | 25 | 25 | 25 | 25 | 25 | 25 |
| Female participants | 25 | 25 | 25 | 25 | 25 | 25 |
| Completed | 24 | 22 | 25 | 23 | 25 | 24 |
| Not completed | 1 | 3 | 0 | 2 | 0 | 1 |
| Withdrew: Physician decision | 1 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom A compared to the Control NRL Condom, over a 4-week assessment period. This outcome was to measure the per participant's average IELT time per condom type. The Intravaginal Ejaculation Latency Time (IELT) is the duration from the start of vaginal entry (vaginal penetration into the female partner) until the start of intravaginal ejaculation (release of semen). It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model. This outcome measure data was collected and analyzed for 150 male participants.
| Seconds | Test Condom A | Control NRL Condom |
|---|---|---|
| To Determine the Effectiveness of Benzocaine of the Test Condom A Compared With the Control NRL Condom at Prolonging Time to Ejaculation | 168.40 ± 15.45 | 104.46 ± 15.53 |
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the change from baseline with the Test Condom B compared to the Control NRL Condom, over a 4-week assessment period. This outcome was to measure the per participant's average IELT time per condom type. It did not analyze all condom uses or sexual encounters as a unit, rather those were taken as an average per participant, in order to effectively run a Generalized Linear Mixed Model. This outcome measure data was collected and analyzed for 150 male participants.
| Seconds | Test Condom B | Control NRL Condom |
|---|---|---|
| To Determine the Effectiveness of Benzocaine of the Test Condom B Compared With the Control NRL Condom at Prolonging Time to Ejaculation | 124.96 ± 15.31 | 104.46 ± 15.53 |
Participants recorded the duration from vaginal entry to ejaculation for each condom use. The outcome was evaluated by the proportion of participants who achieved an increase of 2, 3 and 4 minutes from baseline in each of the Test Condom A and Test Condom B compared to the Control NRL Condom. The odds ratio compares the odds of achieving a given duration increase (e.g., ≥2 minutes) with Test Condom A or B to the odds of achieving the same increase with the Control Condom. An odds ratio greater than 1 suggests the test condom is more effective than the control in helping participants reach that milestone. This outcome measure data was collected and analyzed for 150 male participants.
| Odd ratios | Test Condom A | Test Condom B |
|---|---|---|
| 2 mins | 1.58 (0.98 to 2.55) | 1.36 (0.84 to 2.19) |
| 3 mins | 1.72 (1.04 to 2.84) | 1.25 (0.75 to 2.08) |
| 4 mins | 1.65 (0.95 to 2.86) | 1.22 (0.69 to 2.14) |
The outcome was assessed by the measure of EMSEX (Event-level Male Sexual) pleasure scale questionnaire, a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. EMSEX pleasure scale is a 11-item scale which assesses sexual pleasure at the event level. For each item, the range spans the entirety of the potential range from 0 (zero) to 100 (one hundred). This outcome measure data was collected and analyzed for 150 male participants.
| Total EMSEX pleasure score mean value | Test Condom A | Test Condom B | Control NRL Condom |
|---|---|---|---|
| To Evaluate the Sexual Pleasure When Using the Test Condom A or Test Condom B Compared With the Control NRL Condom | 69.93 (67.40 to 72.50) | 69.67 (67.20 to 72.20) | 68.93 (66.60 to 71.30) |
The outcome was assessed by the measure of Patient Global Impression of Change (PGIC), a subject perceived questionnaire, at the end of a 4-week assessment period when using Test Condom A or Test Condom B compared with the Control NRL Condom. The PGIC is a 7-point response scale (Very much better, Better, Little better, No change, Little worse, Worse, Very much worse). This outcome measure data was collected and analyzed for 150 male participants.
| participants | Test Condom A | Test Condom B | Control NRL Condom |
|---|---|---|---|
| Not Applicable | 5 | 3 | 4 |
| Very Much Better | 12 | 6 | 5 |
| Better | 47 | 46 | 38 |
| Little Better | 49 | 55 | 46 |
| No Change | 32 | 31 | 44 |
| Little Worse | 1 | 4 | 5 |
| Worse | 1 | 2 | 6 |
| Very Much Worse | 1 | 1 | 0 |
Upon completion of each condom assessment period, each participant was required to complete a SPQ. The questionnaire collected the following information (including but not limited to): experience with condom use, acceptability, preference and tolerability. This outcome measure data was collected and analyzed for 150 male participants.
| participants | Test Condom A | Test Condom B | Control NRL Condom |
|---|---|---|---|
| Q1. Overall, how satisfied are you with the effectiveness of this condom? Not Applicable | 4 | 5 | 4 |
| Q1. Very dissatisfied | 6 | 7 | 10 |
| Q1. Somewhat dissatisfied | 18 | 23 | 27 |
| Q1. Neither dissatisfied or satisfied | 37 | 32 | 29 |
| Q1.Somewhat satisfied | 64 | 70 | 68 |
| Q1. Very satisfied | 19 | 11 | 10 |
| Q2. Tolerability gentleness of this condom on the intimate area? Not Applicable | 4 | 5 | 4 |
| Q2. Very dissatisfied | 5 | 7 | 5 |
| Q2. Somewhat dissatisfied | 29 | 14 | 27 |
| Q2. Neither dissatisfied or satisfied | 28 | 25 | 26 |
| Q2. Somewhat satisfied | 63 | 83 | 63 |
| Q2. Very satisfied | 19 | 14 | 23 |
| Q3.Overall, how satisfied are you with the usability (ease of use) of this condom? Not Applicable | 5 | 5 | 4 |
| Q3. Very dissatisfied | 8 | 1 | 3 |
| Q3. Somewhat dissatisfied | 8 | 12 | 11 |
| Q3. Neither dissatisfied or satisfied | 15 | 18 | 16 |
| Q3. Somewhat satisfied | 62 | 73 | 74 |
| Q3. Very satisfied | 50 | 39 | 40 |
Number of clinical failure events per usages (clinical slippage or clinical breakage) reported by participants. The number of outcomes are based on the number of sexual encounters while wearing one of the three condoms being tested. This outcome measure data was collected and analyzed for 150 male participants.
| Percent of condoms that failed | Test Condom A | Test Condom B | Control NRL Condom |
|---|---|---|---|
| Total Clinical Failure Rate of Each Type of Condoms | 2.0 | 1.4 | 0.6 |
Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant. The result is presented by the counts of all AEs sorted by SOC and PT for male participants. This outcome measure data was collected and analyzed for 150 male participants.
| Number of AEs | Test Condom A | Test Condom B | Control NRL Condom | Baseline |
|---|---|---|---|---|
| Baseline / Infections and infestations / Gastrointestinal infection | 0 | 0 | 0 | 1 |
| Baseline / Infections and infestations / Nasopharyngitis | 0 | 0 | 0 | 12 |
| Baseline / Infections and infestations / Tonsillitis | 0 | 0 | 0 | 1 |
| Baseline / Injury, poisoning and procedural complications / Muscle rupture | 0 | 0 | 0 | 1 |
| Baseline / Injury, poisoning and procedural complications / Thermal burn | 0 | 0 | 0 | 1 |
| Gastrointestinal disorders / Gastrointestinal disorder | 0 | 0 | 1 | 0 |
| Infections and infestations / Covid-19 | 2 | 1 | 1 | 0 |
| Infections and infestations / Nasopharyngitis | 2 | 8 | 6 | 0 |
| Infections and infestations / Norovirus infection | 0 | 0 | 1 | 0 |
| Injury, poisoning and procedural complications / Intentional device misuse | 2 | 1 | 1 | 0 |
| Injury, poisoning and procedural complications / Ligament sprain | 1 | 0 | 0 | 0 |
| Injury, poisoning and procedural complications / Epicondylitis | 0 | 0 | 1 | 0 |
| Injury, poisoning and procedural complications / Procedural pain | 0 | 0 | 1 | 0 |
| Reproductive system and breast disorders / Ejaculation failure | 1 | 0 | 0 | 0 |
| Reproductive system and breast disorders / Genital hypoaesthesia | 1 | 0 | 0 | 0 |
| Vascular disorders / Hypertension | 1 | 0 | 1 | 0 |
| Surgical and medical procedures / Wisdom teeth removal | 0 | 0 | 1 | 0 |
Overall proportion of participants with Adverse Events/Adverse Device Effects (AE/ADEs) i.e. the occurrence of one of more AE/ADE per participant. The result is presented by the counts of all AEs sorted by SOC and PT for male participants. This outcome measure data was collected and analyzed for 150 female participants.
| Number of AEs | Test Condom A | Test Condom B | Control NRL Condom | Baseline |
|---|---|---|---|---|
| Baseline / Infections and infestations / COVID-19 | 0 | 0 | 0 | 1 |
| Baseline / Infections and infestations / Nasopharyngitis | 0 | 0 | 0 | 5 |
| Baseline / Infections and infestations / Tonsillitis | 0 | 0 | 0 | 1 |
| Infections and infestations / COVID-19 | 2 | 0 | 1 | 0 |
| Reproductive system and breast disorders / Genital hypoaesthesia | 1 | 0 | 0 | 0 |
| Reproductive system and breast disorders / Vulvovaginal inflammation | 2 | 0 | 0 | 0 |
| Endocrine disorders / Hypothyroidism | 0 | 1 | 0 | 0 |
| Infections and infestations / Nasopharyngitis | 0 | 2 | 3 | 0 |
| Infections and infestations / Pharyngitis | 0 | 1 | 0 | 0 |
| Metabolism and nutrition disorders / Vitamin D deficiency | 0 | 1 | 0 | 0 |
| Reproductive system and breast disorders / Vulvovaginal dryness | 0 | 1 | 0 | 0 |
| Gastrointestinal disorders Gastrointestinal disorder / Gastrointestinal disorder | 0 | 0 | 1 | 0 |
| Reproductive system and breast disorders / Vulvovaginal pain | 0 | 0 | 1 | 0 |
| Respiratory, thoracic and mediastinal disorders / Sinus congestion | 0 | 0 | 1 | 0 |
| Skin and subcutaneous tissue disorders / Dermatitis atopic | 0 | 0 | 1 | 0 |
Collected over 19 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Test Condom A - Males | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Test Condom B - Males | 0/150 (0%) | 0/150 (0%) | 8/150 (5.3%) |
| Control NRL Condom - Males | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Baseline - Males | 0/150 (0%) | 0/150 (0%) | 11/150 (7.3%) |
| Test Condom A - Females | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Test Condom B - Females | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Control NRL Condom - Females | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Baseline - Females | 0/150 (0%) | 0/150 (0%) | 0/150 (0%) |
| Event | Test Condom A - Males | Test Condom B - Males | Control NRL Condom - Males | Baseline - Males | Test Condom A - Females | Test Condom B - Females | Control NRL Condom - Females | Baseline - Females |
|---|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/150 | 8/150 | 0/150 | 11/150 | 0/150 | 0/150 | 0/150 | 0/150 |
150 couples were enrolled. Age and safety were collected for both male and female participants. Other endpoints were analyzed for male participants' data only.
| Age, Customized(years) | Overall Study |
|---|---|
| Male Participants | 33.94 ± 10.38 |
| Female Participants | 32.11 ± 10.14 |
| Sex: Female, Male(Participants) | Overall Study |
|---|---|
| Female | 150 |
| Male | 150 |
| Race/Ethnicity, Customized(Participants) | Overall Study |
|---|---|
| Caucasian | 138 |
| Asian | 7 |
| Black | 1 |
| Other | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — IPD will be shared as per local regulations.
This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ejaculatory Dysfunction
Reckitt Benckiser Healthcare (UK) Limited →